# ClinicalTrials.gov record NCT00672074

> PeptideScanner retained ClinicalTrials.gov record NCT00672074 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-04-14, and PeptideScanner's reviewed identity mapping was ipamorelin.

- Evidence object: `story:clinicaltrials-gov-nct00672074-ipamorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-04-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00672074-ipamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct00672074-ipamorelin-v1.json
- Content SHA-256: `0b362bee3d683d389e614e5fa1201eb498d728817eddd84f387cf1756020bdba`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT00672074 ([`ctg-observation-nct00672074-2017-04-14-09c53b030764`](#source-ctg-observation-nct00672074-2017-04-14-09c53b030764))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00672074 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-04-14, and PeptideScanner's reviewed identity mapping was ipamorelin. ([`ctg-observation-nct00672074-2017-04-14-09c53b030764`](#source-ctg-observation-nct00672074-2017-04-14-09c53b030764))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00672074 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-04-14, and PeptideScanner's reviewed identity mapping was ipamorelin. ([`ctg-observation-nct00672074-2017-04-14-09c53b030764`](#source-ctg-observation-nct00672074-2017-04-14-09c53b030764))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00672074-2017-04-14-09c53b030764`](#source-ctg-observation-nct00672074-2017-04-14-09c53b030764))

## Sources

<a id="source-ctg-observation-nct00672074-2017-04-14-09c53b030764"></a>
- **ClinicalTrials.gov record NCT00672074 · retained source version 2017-04-14:09c53b0307646dc9a23da8c7537ff9ca529da26aa628f0bcc0f160d5c7377750** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00672074) (`ctg-observation-nct00672074-2017-04-14-09c53b030764`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00672074." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct00672074-ipamorelin-v1.json SHA-256: 0b362bee3d683d389e614e5fa1201eb498d728817eddd84f387cf1756020bdba.